While the Rb1∆L mutation enhances tumorigenesis when combined with p53 loss the same mutation does not cooperate with oncogene activation in the receptor tyrosine kinase (RTK)-ras pathway to promote tumor formation. Here, TP53 is linked to neoplasm.